Clinical trial
A Real-World Study of FOLFOX Combined With Panitumumab N01 Versus Cetuximab as First-Line Treatment for RAS Wild-Type Metastatic Colorectal Cancer
NCT07917429 is registered in ClinicalTrials.gov with Fujian Medical University Union Hospital as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started January 2027. Observational study, 610 participants (estimated). Lead sponsor Fujian Medical University Union Hospital; China. Primary measures: overall survival; Incremental Cost-Utility Ratio (ICUR).
How it compares
1,394 similar trials: same condition (Colorectal Neoplasms) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Real-World Study of FOLFOX Combined With Panitumumab N01 Versus Cetuximab as First-Line Treatment for RAS Wild-Type Metastatic Colorectal Cancer
- Lead sponsor
- Fujian Medical University Union Hospital
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- June 1, 2030
- Enrollment
- 610 (estimated)
- Sites
- 1
Conditions
MeSH condition names; the registry's own terms follow.
Registry terms: colorectal cancer metastatic
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Observational
- Sites
- 1
- Countries
- China
- Lead sponsor
- Fujian Medical University Union Hospital
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Panitumumab N01 | Panitumumab N01 | |
Show registry wordingPanitumumab N01 plus FOLFOX | ||
| Cetuximab | Cetuximab (EGFR inhibitor) | |
Show registry wordingCetuximab or Cetuximab N01 plus FOLFOX | ||
Primary endpoints
Registered primary outcome measures; 2 primary.
| Measure | Time frame |
|---|---|
| overall survival | From date of first diagnosis of RAS wild-type metastatic colorectal cancer until date of death from any cause, assessed up to 30 months |
Show registry wordingTime from the index-date (initial diagnosis of RAS wild-type mCRC) to death from any cause. Patients alive or lost-to-follow-up will be censored at the date of last valid follow-up. | |
| Incremental Cost-Utility Ratio (ICUR) | From date of treatment initiation until date of study completion, death, or loss to follow-up, whichever comes first, assessed up to 30 months |
Show registry wordingRatio of incremental direct medical costs versus incremental quality-adjusted life-years (QALYs) between the Panitumumab N01 arm and the cetuximab/cetuximab N01 arm; unit: CNY per QALY. Only costs generated after Panitumumab N01 is listed for national medical reimbursement are included. | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
CETUXIMAB
- US 6217866; expires February 12, 2018; assignee Rhone-Poulenc Rorer International (Holdings), Inc.
Lead sponsor's other trials
Fujian Medical University Union Hospital, most recent start first.
+103 more trials
Similar trials
Same condition (Colorectal Neoplasms) and phase, most recent start first.
+1,389 more trials See the condition page